We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.50 | -0.41% | 1,583.50 | 1,582.50 | 1,583.00 | 1,595.50 | 1,580.00 | 1,593.00 | 5,931,081 | 16:35:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.22 | 65.15B |
By Razak Musah Baba
LONDON--Canada has granted GlaxoSmithKline PLC's (GSK.LN) Incruse Ellipta drug its first marketing authorization for the treatment of lung diseases, the British pharmaceutical company said Thursday.
Incruse Ellipta is a new once-daily treatment approved in Canada for treatment of airflow obstruction with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Following the decision, the company is now looking to progress the regulatory submissions elsewhere, said Darrell Baker, SVP & Head, Glaxo Global Respiratory Franchise.
Glaxo shares closed Thursday at GBP15.59, valuing the company at GBP75.76 billion.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions